Sotac Pharmaceuticals Ltd
Incorporated in 2015, Sotac Pharmaceuticals
Ltd manufactures and sells a wide range of pharmaceutical products[1]
- Market Cap ₹ 116 Cr.
- Current Price ₹ 105
- High / Low ₹ 203 / 87.1
- Stock P/E 25.5
- Book Value ₹ 42.7
- Dividend Yield 0.00 %
- ROCE 10.0 %
- ROE 11.2 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Working capital days have increased from 60.2 days to 92.3 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|
| 29 | 49 | 77 | 104 | 105 | |
| 27 | 47 | 70 | 95 | 96 | |
| Operating Profit | 2 | 1 | 7 | 9 | 8 |
| OPM % | 7% | 3% | 10% | 8% | 8% |
| 0 | 0 | 1 | 0 | 1 | |
| Interest | 0 | 1 | 2 | 2 | 2 |
| Depreciation | 1 | 3 | 2 | 3 | 3 |
| Profit before tax | 0 | -2 | 4 | 4 | 4 |
| Tax % | 75% | 15% | 42% | 10% | |
| 0 | -2 | 2 | 4 | 4 | |
| EPS in Rs | 0.39 | -10.30 | 3.58 | 3.87 | 4.04 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 29% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 52% |
| TTM: | 49% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 8 | 11 | 11 |
| Reserves | 1 | 0 | 11 | 34 | 36 |
| 13 | 17 | 22 | 25 | 28 | |
| 14 | 15 | 32 | 35 | 40 | |
| Total Liabilities | 30 | 35 | 74 | 105 | 116 |
| 16 | 17 | 26 | 36 | 39 | |
| CWIP | 0 | 0 | 0 | 5 | 9 |
| Investments | 0 | 0 | 0 | 2 | 6 |
| 14 | 18 | 48 | 63 | 62 | |
| Total Assets | 30 | 35 | 74 | 105 | 116 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 0 | -0 | 8 | -16 | |
| -12 | -3 | -12 | -20 | |
| 11 | 3 | 13 | 30 | |
| Net Cash Flow | -0 | -0 | 10 | -6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 89 | 44 | 70 | 92 |
| Inventory Days | 40 | 45 | 87 | 83 |
| Days Payable | 194 | 121 | 162 | 132 |
| Cash Conversion Cycle | -66 | -32 | -5 | 43 |
| Working Capital Days | 14 | 15 | 28 | 92 |
| ROCE % | -5% | 10% |
Documents
Announcements
-
Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
29 January 2025 - SOTAC PHARMACEUTICALS LIMITED has informed about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent
-
Appointment
28 January 2025 - Sotac Pharmaceuticals Limited has informed regarding Appointment of Mr Pankaj Prabhakar Mahabaleshwarkar as Chief Operating Officer of the company w.e.f. January 28, 2025.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
13 January 2025 - Sotac Pharmaceuticals Limited has informed about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
-
Updates
8 January 2025 - Sotac Pharmaceuticals Limited has informed regarding Submission of Non-Applicability of the Regulation 27(2) of the SEBI (LODR) Regulations, 2015.
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
8 January 2025 - Sotac Pharmaceuticals Limited has informed regarding Submission of Non-Applicability of the Regulation 27(2) of the SEBI (LODR)Regulations, 2015.
Business Overview:[1]
SPL specializes in manufacturing a broad range of pharmaceutical products across various therapeutic areas, including anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological treatments, antacids, anti-ulcer (PPI), anti-emetics, cardiac, antihypertensives, analgesic, antipyretic, anti-inflammatory, antibacterial, antiviral, general antibiotics (β-lactams and non-β-lactams), antifungal, and cephalosporins.